We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 31Floors who wrote (49058)9/1/2019 12:40:41 PM
From: 31Floors  Read Replies (1) of 49325
It's a bit ironic that the only NR IPA has issued about signing a large pharmaceutical co is this one, a top 15 for its hibridoma platform and not B cell Select(tm) or DeepDisplay (tm).

It's the B cell Select platform that is the most prominent platform that's caught the attention of multiple majors (direct view into B cells to show much greater depth allowing the selection of many more candidates vs traditional B cell discovery methods.

Anyway, this agreement from last October serves as a hint of how well rounded IPA is as a full service Antibody discovery CRO.


It's totally expected to see IPA sell off into the mid .50s after the disappointing Q4 Numbers. More discerning or perhaps less pained shareholders may have kept in mind that the quarter just reported ended one month PRIOR to this NR. Fingers crossed to see some revenues from the following programs recognized in Q1 ending July 31 and Q2. Let's break this $3m /quarter glass ceiling!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext